Phase III BMS-790052 Add-On to Peg-Interferon Alfa-2a and Ribavirin in Naive Hepatitis C

Inclusion Criteria:

- Participants chronically infected with HCV Genotype 4

- HCV RNA viral load of ≥ 10,000 IU/mL

- No previous exposure to an interferon formulation, RBV or HCV direct antiviral agent

- Results of a liver biopsy obtained within three years prior to enrollment to
demonstrate the absence of cirrhosis. Participants with compensated cirrhosis are
permitted, however, and any prior biopsy is permitted

Exclusion Criteria:

- Evidence of decompensated liver disease

- Documented or suspected Hepatocellular carcinoma (HCC)

- Positive for Hepatitis B surface antigen (HBsAg) or Human immunodeficiency virus-1
(HIV-1)/HIV-2 antibody at screening